MISSION

The Group aims to improve the clinical care of patients suffering with cutaneous or ocular (eye) melanoma, and to increase knowledge about melanoma acquisition and progression. Group sub-committees focus on topics including epidemiology, early stage melanoma, surgery, pathology and systemic therapy (adjuvant and for advanced disease).

PRACTICE CHANGING RESEARCH

  • Melanoma Group

    EORTC 18991 – Adjuvant PegIntron treatment in stage III melanoma versus observation after regional lymph node dissection.

    A Multicenter Randomized Phase III trial.

    EORTC study comparing two treatment regimens for patients with stage III melanoma, found that additional immunotherapy (IFN alpha 2-b) impaired their health-related quality of life (HRQOL) scores. This study helped highlight that adjuvant immunotherapy may not be the most appropriate treatment for high-risk melanoma patients.

    READ MORE

  • Melanoma Group

    EORTC 18952 – Post-operative adjuvant Interferon-alpha 2b (Intron-A) treatment after resection of thick primary melanoma and/or regional lymphnode metastases “intermediate-high dose” vs “intermediate-low dose” Interferon-alpha vs observation.

    Randomized phase III trial.

    EORTC found that additional interferon treatment improves overall survival, in patients with stage III ulcerated melanoma.

    READ MORE

  • Melanoma Group

    EORTC 18021 – Intravenous versus intra-arterial fotemustine chemotherapy in patients with liver metastases from uveal melanoma : a randomized phase III study of the EORTC Melanoma Group.

    Uveal melanoma (UM) is a rare disease arising from the pigmented uveal tract of the eye, with cancerous cells spreading in 95% of patients in liver. Therefore, this EORTC trial evaluated the effectiveness of delivering treatment of fotemustine via hepatic intra-arterial (HIA) vs intra-venously (IV) in patients with liver metastases from uveal melanoma. Results showed that hepatic intra-arterial (HIA) delivery of fotemustine did not improve overall survival compared to intravenous delivery in patients with uveal melanoma.

    READ MORE

  • Melanoma Group

    EORTC 18071 – Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma.

    A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group.

    EORTC found that resection of lymph nodes plus three years of additional treatment with ipilimumab, prolongs the time to disease reoccurrence or death in patients with stage III melanoma. A follow up in 2016 confirmed these results and showed that additional treatment with ipilimumab also improves overall survival.

    READ MORE

  • Melanoma Group

    EORTC 16032 – Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma.

    Some Melanoma metastasis contain the MAGE-A3 antigen which can be targeted by special antitumor immune cells. This EORTC study compared two treatments in patients with metastatic melanoma expressing MAGE-A3, and found that immunization against MAGE-A3 improved overall survival. The EORTC Melanoma Group also reported that the females have longer time to reoccurrence and improved overall survival than males in stage II-IV melanoma patients.

    READ MORE

  • Melanoma Group

    EORTC1325 – Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma.

    A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group.

    EORTC found that 1-year of therapy with immunotherapy treatment (pembrolizumab) after surgery, significantly prolongs time to disease recurrence or death, in patients with high-risk stage III resected melanoma. Based on these results, pembrolizumab treatment was approved by the EMA and FDA.

    READ MORE

  • Jun-09
  • Nov-11
  • May-14
  • Nov-16
  • Dec-16
  • May-18

LATEST PUBLICATIONS

Want to read in detail our scientific findings on specific tumour type?
Search through our comprehensive list of EORTC published articles to date.

Search for an article
Sign up